Literature DB >> 17215390

Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice.

Yaoming Wang1, Xiao Ou Mao, Lin Xie, Surita Banwait, Hugo H Marti, David A Greenberg, Kunlin Jin.   

Abstract

We sought genetic evidence for the involvement of neuronal vascular endothelial growth factor (VEGF) in amyotrophic lateral sclerosis (ALS). Mice expressing human ALS mutant superoxide dismutase-1 (SOD1) were crossed with mice that overexpress VEGF in neurons (VEGF+/+). We report that SOD1(G93A)/VEGF+/+ double-transgenic mice show delayed motor neuron loss, delayed motor impairment, and prolonged survival compared with SOD1(G93A) single transgenics. These findings indicate that neuronal VEGF protects against motor neuron degeneration, and may have therapeutic implications for ALS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17215390      PMCID: PMC2830908          DOI: 10.1523/JNEUROSCI.4433-06.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  17 in total

Review 1.  Amyotrophic lateral sclerosis.

Authors:  L P Rowland; N A Shneider
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

2.  Mutant Cu/Zn-superoxide dismutase proteins have altered solubility and interact with heat shock/stress proteins in models of amyotrophic lateral sclerosis.

Authors:  G A Shinder; M C Lacourse; S Minotti; H D Durham
Journal:  J Biol Chem       Date:  2001-01-22       Impact factor: 5.157

3.  Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia.

Authors:  K L Jin; X O Mao; D A Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

4.  Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.

Authors:  B Oosthuyse; L Moons; E Storkebaum; H Beck; D Nuyens; K Brusselmans; J Van Dorpe; P Hellings; M Gorselink; S Heymans; G Theilmeier; M Dewerchin; V Laudenbach; P Vermylen; H Raat; T Acker; V Vleminckx; L Van Den Bosch; N Cashman; H Fujisawa; M R Drost; R Sciot; F Bruyninckx; D J Hicklin; C Ince; P Gressens; F Lupu; K H Plate; W Robberecht; J M Herbert; D Collen; P Carmeliet
Journal:  Nat Genet       Date:  2001-06       Impact factor: 38.330

5.  The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis.

Authors:  Y Yang; A Hentati; H X Deng; O Dabbagh; T Sasaki; M Hirano; W Y Hung; K Ouahchi; J Yan; A C Azim; N Cole; G Gascon; A Yagmour; M Ben-Hamida; M Pericak-Vance; F Hentati; T Siddique
Journal:  Nat Genet       Date:  2001-10       Impact factor: 38.330

6.  Paracrine and autocrine functions of neuronal vascular endothelial growth factor (VEGF) in the central nervous system.

Authors:  Omolara O Ogunshola; Anica Antic; Maria J Donoghue; Shou-Yuan Fan; Hyun Kim; William B Stewart; Joseph A Madri; Laura R Ment
Journal:  J Biol Chem       Date:  2002-01-03       Impact factor: 5.157

7.  A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2.

Authors:  S Hadano; C K Hand; H Osuga; Y Yanagisawa; A Otomo; R S Devon; N Miyamoto; J Showguchi-Miyata; Y Okada; R Singaraja; D A Figlewicz; T Kwiatkowski; B A Hosler; T Sagie; J Skaug; J Nasir; R H Brown; S W Scherer; G A Rouleau; M R Hayden; J E Ikeda
Journal:  Nat Genet       Date:  2001-10       Impact factor: 38.330

8.  VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death.

Authors:  Diether Lambrechts; Erik Storkebaum; Masafumi Morimoto; Jurgen Del-Favero; Frederik Desmet; Stefan L Marklund; Sabine Wyns; Vincent Thijs; Jörgen Andersson; Ingrid van Marion; Ammar Al-Chalabi; Stephanie Bornes; Rhiannon Musson; Valerie Hansen; Lars Beckman; Rolf Adolfsson; Hardev Singh Pall; Hervé Prats; Severine Vermeire; Paul Rutgeerts; Shigehiro Katayama; Takuya Awata; Nigel Leigh; Loïc Lang-Lazdunski; Mieke Dewerchin; Christopher Shaw; Lieve Moons; Robert Vlietinck; Karen E Morrison; Wim Robberecht; Christine Van Broeckhoven; Désiré Collen; Peter M Andersen; Peter Carmeliet
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

9.  DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4).

Authors:  Ying-Zhang Chen; Craig L Bennett; Huy M Huynh; Ian P Blair; Imke Puls; Joy Irobi; Ines Dierick; Annette Abel; Marina L Kennerson; Bruce A Rabin; Garth A Nicholson; Michaela Auer-Grumbach; Klaus Wagner; Peter De Jonghe; John W Griffin; Kenneth H Fischbeck; Vincent Timmerman; David R Cornblath; Phillip F Chance
Journal:  Am J Hum Genet       Date:  2004-04-21       Impact factor: 11.025

10.  VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.

Authors:  Mimoun Azzouz; G Scott Ralph; Erik Storkebaum; Lucy E Walmsley; Kyriacos A Mitrophanous; Susan M Kingsman; Peter Carmeliet; Nicholas D Mazarakis
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

View more
  65 in total

1.  Evolution of the VEGF-regulated vascular network from a neural guidance system.

Authors:  Sreenivasan Ponnambalam; Mario Alberghina
Journal:  Mol Neurobiol       Date:  2011-01-28       Impact factor: 5.590

2.  Multiple neurotrophic effects of VEGF on cultured neurons.

Authors:  Alma Sanchez; Suchin Wadhwani; Paula Grammas
Journal:  Neuropeptides       Date:  2010-04-28       Impact factor: 3.286

Review 3.  Current Neurogenic and Neuroprotective Strategies to Prevent and Treat Neurodegenerative and Neuropsychiatric Disorders.

Authors:  I M Carvalho; P B Coelho; P C Costa; C S Marques; R S Oliveira; D C Ferreira
Journal:  Neuromolecular Med       Date:  2015-09-15       Impact factor: 3.843

Review 4.  Motor neuron trophic factors: therapeutic use in ALS?

Authors:  Thomas W Gould; Ronald W Oppenheim
Journal:  Brain Res Rev       Date:  2010-10-21

Review 5.  Roles for VEGF in the adult.

Authors:  Arindel S R Maharaj; Patricia A D'Amore
Journal:  Microvasc Res       Date:  2007-04-06       Impact factor: 3.514

Review 6.  Gene and protein therapies utilizing VEGF for ALS.

Authors:  Orion P Keifer; Deirdre M O'Connor; Nicholas M Boulis
Journal:  Pharmacol Ther       Date:  2013-10-29       Impact factor: 12.310

7.  Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?

Authors:  Alexandre Henriques; Claudia Pitzer; Armin Schneider
Journal:  Front Neurosci       Date:  2010-06-11       Impact factor: 4.677

8.  Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells.

Authors:  Vikram S Brar; Rajesh K Sharma; Ravi K Murthy; K V Chalam
Journal:  Mol Vis       Date:  2010-09-12       Impact factor: 2.367

Review 9.  Targeting angiogenin in therapy of amyotropic lateral sclerosis.

Authors:  Hiroko Kishikawa; David Wu; Guo-fu Hu
Journal:  Expert Opin Ther Targets       Date:  2008-10       Impact factor: 6.902

10.  Progranulin is expressed within motor neurons and promotes neuronal cell survival.

Authors:  Cara L Ryan; David C Baranowski; Babykumari P Chitramuthu; Suneil Malik; Zhi Li; Mingju Cao; Sandra Minotti; Heather D Durham; Denis G Kay; Christopher A Shaw; Hugh P J Bennett; Andrew Bateman
Journal:  BMC Neurosci       Date:  2009-10-27       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.